Inhibikase Therapeutics, Inc. financial data

Symbol
IKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3350 Riverwood Parkway Se, Suite 1900, Atlanta, GA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 232 % -70%
Debt-to-equity 73.7 % +377%
Return On Equity -351 % -270%
Return On Assets -202 % -146%
Operating Margin -2.01B % -32475675%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.2M shares +988%
Common Stock, Shares, Outstanding 7.46M shares +39.2%
Entity Public Float 19.1M USD +2.14%
Common Stock, Value, Issued 7.46K USD +39.2%
Weighted Average Number of Shares Outstanding, Basic 8.88M shares +66.3%
Weighted Average Number of Shares Outstanding, Diluted 8.88M shares +66.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1 USD -100%
Research and Development Expense 13M USD -4.75%
Costs and Expenses 20.1M USD -1.38%
Operating Income (Loss) -20.1M USD -0.21%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -19.6M USD -2.28%
Earnings Per Share, Basic -2.66 USD/shares +45.6%
Earnings Per Share, Diluted -2.66 USD/shares +45.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.17M USD +27.5%
Marketable Securities, Current 2.33M USD +18.3%
Assets, Current 4.19M USD -76.1%
Property, Plant and Equipment, Net 53.7K USD -32.9%
Operating Lease, Right-of-Use Asset 133K USD -46.8%
Assets 4.38M USD -75.5%
Accounts Payable, Current 2.53M USD +244%
Accrued Liabilities, Current 2.16M USD +16.3%
Liabilities, Current 4.91M USD +79%
Operating Lease, Liability, Noncurrent 25.6K USD -82.9%
Liabilities 4.91M USD +71.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.75K USD
Retained Earnings (Accumulated Deficit) -82.3M USD -31.2%
Stockholders' Equity Attributable to Parent -531K USD -104%
Liabilities and Equity 4.38M USD -75.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.87M USD +35.2%
Net Cash Provided by (Used in) Financing Activities 367K USD -95.7%
Net Cash Provided by (Used in) Investing Activities -3.31M USD +43.3%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 7.46M shares +39.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 913K USD -93.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 18.8M USD +51.5%
Deferred Tax Assets, Gross 18.8M USD +51.5%
Operating Lease, Liability 145K USD -46.2%
Depreciation 26.3K USD -85.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.78M USD -25.7%
Lessee, Operating Lease, Liability, to be Paid 153K USD
Property, Plant and Equipment, Gross 104K USD 0%
Operating Lease, Liability, Current 152K USD +2.88%
Lessee, Operating Lease, Liability, to be Paid, Year Two 115K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.08K USD -75%
Deferred Tax Assets, Operating Loss Carryforwards 9.18M USD +33.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.97K USD
Share-based Payment Arrangement, Expense 354K USD -25.9%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%